Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504645 | 0.83 | TDP1 (0.44) | TDP1CACNA1HMTNR1AMTNR1BFUCA1 | |
| SCHEMBL48633 | 0.81 | — | — | |
| SCHEMBL13165688 | 0.81 | TDP1 (0.58) | TDP1CACNA1HMTNR1AMTNR1BFUCA1 | |
| Hydrochloric Acid SCHEMBL4553435 | 0.79 | — | — | |
| SCHEMBL21695528 | 0.78 | TDP1 (0.42) | TDP1CACNA1HTLR4MTNR1AMTNR1B | |
| SCHEMBL1898034 | 0.78 | NPC1 (0.44) | TDP1CACNA1HMTNR1AMTNR1BFUCA1 | |
| SCHEMBL23236485 | 0.76 | KMT2A (0.45) | TDP1EPHX1 | |
| SCHEMBL6643358 | 0.76 | KMT2A (0.45) | TDP1EPHX1 | |
| SCHEMBL10147958 | 0.76 | CYP2D6 (0.56) | TDP1CACNA1HMTNR1AMTNR1BFUCA1 | |
| SCHEMBL14013458 | 0.76 | CYP2D6 (0.56) | TDP1CACNA1HMTNR1AMTNR1BFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11027242-B2 | Nanofiltration membranes and methods of use | NOVOMER, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190255488-A1 | NANOFILTRATION MEMBRANES AND METHODS OF USE | NOVOMER, INC. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255488-A1 | NANOFILTRATION MEMBRANES AND METHODS OF USE | MLEC, EPCAM, LNPK | TDP1 4710/4885CACNA1H 4445/4885TLR4 3544/4885 |
| US-11027242-B2 | Nanofiltration membranes and methods of use | MLEC, EPCAM, LNPK | TDP1 4710/4885CACNA1H 4445/4885TLR4 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.